Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.68 |
| ▸ | CA1 | P00915 | 13/20 | 0.68 |
| ▸ | CA9 | Q16790 | 11/20 | 0.68 |
| ▸ | CA12 | O43570 | 9/20 | 0.68 |
| ▸ | CA7 | P43166 | 7/20 | 0.68 |
| ▸ | CA4 | P22748 | 5/20 | 0.68 |
| ▸ | CA6 | P23280 | 5/20 | 0.68 |
| ▸ | CA5A | P35218 | 5/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.68 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044622 | 0.82 | CA2 (0.46) | CA2CA1CA9CA12CA7 | |
| SCHEMBL21487215 | 0.81 | CA2 (0.63) | CA2CA1CA9CA12CA7 | |
| SCHEMBL4603717 | 0.81 | CA2 (0.69) | CA2CA1CA9CA12CA7 | |
| SCHEMBL27275498 | 0.81 | CA2 (0.57) | CA2CA1CA9CA12CA7 | |
| SCHEMBL30753315 | 0.81 | CA2 (0.57) | CA2CA1CA9CA12CA7 | |
| SCHEMBL878968 | 0.81 | CA2 (1.00) | CA2CA1CA9CA12CA7 | |
| SCHEMBL30351262 | 0.81 | CA2 (1.00) | CA2CA1CA9CA12CA7 | |
| SCHEMBL1368195 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA7 | |
| SCHEMBL5805029 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA7 | |
| SCHEMBL15068035 | 0.79 | CA2 (0.61) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100475787-C | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | LILLY CO ELI (US) | 2009-04-08 | — | — | CN | disclosed |
| US-7183320-B2 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1401806-B1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | LILLY CO ELI (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY | 2004-08-12 | — | — | US | disclosed |
| CN-1514824-A | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | — | 2004-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | GLS2, GLS, MCL1 | CA2 1688/4885CA1 1310/4885CA9 163/4885 |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | CA2 4361/4885CA1 4795/4885CA9 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.